Aim: Autoimmune diseases are presented with many signs and symptoms. Eyes are commonly involved in these diseases. This study aimed to estimate the prevalence of different ophthalmological complications in patients with and without immune-mediated rheumatological diseases.
Methods: Patients who were referred to Kermanshah's rheumatologic clinics by an ophthalmologist from 2018 to 2020 for a rheumatologist visit were included. A checklist for extracting data from medical files; containing symptoms, organ involvement, ocular diseases diagnosed by an ophthalmologist, rheumatologic diseases diagnosed by a rheumatologist, lab tests, and disease progression was created. After we evaluated the medical data, we found that 54 patients out of 106 were diagnosed to have immune-mediated rheumatological diseases. Patients were divided into two groups; the first group included patients with diagnosed immune-mediated rheumatologic disease and ophthalmic complications; patients with no known immune-mediated rheumatological disease were considered the second group. The obtained information was analyzed using statistical tests.
Results: One hundred and six patients participated in this study, 67% of whom were females. The most common ocular symptom was blurred vision (49%). Involvement of both eyes (43.4%) was more common than single left or right eye involvement. The most common ophthalmic disease was anterior uveitis (35.8%). The most common rheumatologic disease was Behçet's disease (21.7%). Hypertension and hypothyroidism were the most common comorbidities; 36.7% of the patients had skin and mucous involvement, and 37.7% had joint involvement. In follow-up of the ophthalmic symptoms, most patients were controlled partially. Ophthalmic diseases, laboratory tests, joint involvement, skin and mucous involvement, and lung involvement were associated with rheumatologic diseases.
Conclusion: Early diagnosis of ocular involvement in rheumatologic diseases is crucial to prevent adverse complications. The results can be beneficial for a better perception of ophthalmic symptoms and diseases among patients with autoimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165950 | PMC |
| http://dx.doi.org/10.1002/iid3.863 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rheumatologic complications of CAR-T Cell therapy. Experience of a single center.
Semin Arthritis Rheum
December 2024
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Immunology, CDB, Hospital Clínic, Barcelona, Spain.
Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined.
Methods: We conducted a retrospective study to analyze rheumatic complications in 310 patients treated with CAR-T therapy at a single center from January 2020 to May 2024.
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials.
J Autoimmun
December 2024
Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada; Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada. Electronic address:
Objectives: Advanced combination treatment (ACT), defined as a combination of at least 2 biologic agents, a biologic agent and an oral small molecule, 2 oral small molecules drug with different mechanisms of action is a proposed strategy to improve outcomes in patients with immune-mediated inflammatory disease (IMID). We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ACT with monotherapy in patients with select IMIDs.
Methods: Through a systematic literature search, we identified 10 RCTs (n = 1154) comparing ACT with single agent therapy (monotherapy).
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).
Vaccines (Basel)
October 2024
Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Introduction: As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding the risks and impact of SARS-CoV-2 infection and vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from the phase 3 COVID-19 vaccination trials.
Methods: The BELCOMID study collected patient data and serological samples from a large, multicentric IMID patient cohort that was prospectively followed during sequential stages of the pandemic. Patients were stratified according to vaccination status into five groups across three sampling periods.
AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review.
Clin Gastroenterol Hepatol
December 2024
Division of Gastroenterology, University of Utah, Salt Lake City, Utah. Electronic address:
Article Synopsis
- The American Gastroenterological Association (AGA) commissioned this expert review to provide guidance on diagnosing infectious and immune-mediated esophageal disorders, which are often under-recognized and lead to dysfunction and health costs.
- The review offers Best Practice Advice (BPA) statements based on published literature and expert opinions, but lacks formal evidence ratings due to the absence of systematic reviews.
- Increased awareness among gastroenterologists regarding these disorders can enhance patient care by improving diagnosis and limiting unnecessary medical procedures, particularly in patients presenting with dysphagia, heartburn, and odynophagia.
Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study.
Farm Hosp
November 2024
Servicio de Farmacia, Hospital Universitario La Princesa, Madrid, España.
Article Synopsis
- The study aims to assess the health-related quality of life in patients with common immune-mediated inflammatory diseases like IBD, psoriasis, psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies in Spain, considering factors affecting their quality of life.
- The research involved 578 adult patients and utilized various questionnaires, including EQ-5D-5L, to evaluate their quality of life, revealing significant differences based on the type of disease.
- Results showed that psoriasis and IBD patients experienced a better quality of life compared to those with psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies, with worse outcomes linked to female gender, more severe disease, older age, and numerous prior treatments. *
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!